Phreesia, Inc. (PHR) Stock Price & Analysis
Phreesia, Inc. (PHR) rose 4.29% to USD 10.22 as of July 25, 2026 at 07:49 UTC, according to Nexqual real-time market data.
PHR last closed at USD 9.8; the session ranged USD 9.88–10.35 on volume of 895,771 shares. Market capitalization is $631.72M, with a 52-week range of USD 7.77–32.76 (NYQ). Source: Nexqual, July 25, 2026 at 07:49 UTC.
Key Statistics (as of July 25, 2026 at 07:49 UTC)
| Price | USD 10.22 |
|---|---|
| Change | ▲ 4.29% (up) |
| Previous Close | USD 9.8 |
| Open | USD 9.95 |
| Day Range | USD 9.88 – 10.35 |
| 52-Week Range | USD 7.77 – 32.76 |
| Volume | 895,771 shares |
| Market Cap | $631.72M |
| Exchange | NYQ |
Technical Analysis (PHR)
Nexqual's technical model rates PHR "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 07:49 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.36 (neutral) |
| vs SMA50 | Above (USD 9.82) |
| MACD | 0.12 (positive) |
Analyst Ratings (PHR)
Wall Street analysts rate PHR "Buy" based on 17 analysts, with a mean price target of USD 13.94 (range USD 9–20), per Nexqual as of July 25, 2026 at 07:49 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 17 |
| Mean Target | USD 13.94 |
| High Target | USD 20 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 11 / 8 / 0 |
Earnings (PHR)
| Next Earnings Date | 2026-09-03 |
|---|---|
| EPS Estimate | USD 0.32 |
| Revenue Estimate | $128.99M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-04-30 | USD 0.19 vs est 0.29 ▼ miss |
| 2026-01-31 | USD 0.44 vs est 0.32 ▲ beat |
| 2025-10-31 | USD 0.31 vs est 0.24 ▲ beat |
| 2025-07-31 | USD 0.27 vs est 0.19 ▲ beat |
Source: Nexqual, July 25, 2026 at 07:49 UTC.
Financials & Fundamentals (PHR)
| Total Revenue | $495.59M |
|---|---|
| Revenue Growth (YoY) | +12.90% |
| Gross Margin | +67.84% |
| Operating Margin | +5.15% |
| Profit Margin | +1.85% |
| ROE | +2.86% |
| Debt / Equity | 25.78 |
| Current Ratio | 1.76 |
| Total Cash | $74.71M |
| Total Debt | $92.56M |
| Free Cash Flow | $56.36M |
Source: Nexqual, July 25, 2026 at 07:49 UTC.
Financial Health Score (PHR)
Nexqual rates Phreesia, Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 07:49 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 68%, operating 5% |
| Balance Sheet | Strong — $75M cash vs $93M debt |
| Cash Flow | Solid — FCF $56M, 12% margin |
| Efficiency | Weak — ROE 3%, ROA 1.5% |
Ownership (PHR)
| Insider Ownership | +4.38% |
|---|---|
| Institutional Ownership | +97.88% |
| Shares Outstanding | 61.81M |
| Float | 49.92M |
| Short % of Float | +7.02% |
Source: Nexqual, July 25, 2026 at 07:49 UTC.
Leadership (PHR)
Phreesia, Inc. is led by Chaim Indig (age 46), Co-Founder, CEO & Director, per Nexqual as of July 25, 2026 at 07:49 UTC.
| Co-Founder, CEO & Director | Chaim Indig (age 46) |
|---|---|
| Co-Founder & President of Provider Solutions | Evan Roberts (age 45) |
| Chief Financial Officer | Balaji Gandhi (age 50) |
| President of Network Solutions | David Linetsky (age 44) |
| Chief Technology Officer | Jack Callahan |
Major Backers & Investors (PHR)
Notable institutional backers of Phreesia, Inc. include Pale Fire Capital SE, AQR Capital Management, LLC, Algert Global, LLC, according to Nexqual as of July 25, 2026 at 07:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Pale Fire Capital SE | 13.99% |
| AQR Capital Management, LLC | 3% |
| Algert Global, LLC | 2.23% |
| Prosight Management, Lp | 1.78% |
| Jacobs Levy Equity Management, Inc. | 1.74% |
| Fidelity | 0.93% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 17% |
| BlackRock | 12.57% |
| State Street | 2.38% |
| Geode Capital | 2.22% |
Source: Nexqual, July 25, 2026 at 07:49 UTC.
From Phreesia, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Our Platform and Solutions Phreesia's integrated platform is designed to address challenges patients and healthcare providers face in three core areas: Access, Affordability, and Outcomes.
- We have industry certifications, including HITRUST, PCI-DSS Level 1 Service Provider, Systems and Organization Controls 2 ("SOC 2") and PCI Point-to-Point Encryption.
- Accordingly, new competitors or providers of EHR and PM solutions may emerge that have greater market share, larger client bases, more widely adopted proprietary technologies, greater marketing expertise, new or better AI technologies, greater financial resources and larger sales forces than we have, which could put us at a competitive disadvantage and could render our existing or future products less competitive or obsolete.
- In fiscal year 2026, our platform facilitated approximately 180 million patient visits, representing approximately one in six ambulatory patient visits in the United States.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HCAT | Health Catalyst, Inc | USD 2.08 | ▲ 1.96% |
| VCYT | Veracyte, Inc. | USD 56.61 | ▼ 2.41% |
| CSTL | Castle Biosciences, Inc. | USD 24.69 | ▼ 0.5% |
| LOB | Live Oak Bancshares, Inc. | USD 42.08 | ▲ 2.51% |
| HQY | HealthEquity, Inc. | USD 94.64 | ▼ 1.37% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:49 UTC. This page is informational and not investment advice.